Provided by Tiger Fintech (Singapore) Pte. Ltd.

VolitionRX

0.7392
-0.0358-4.62%
Volume:295.45K
Turnover:226.12K
Market Cap:76.15M
PE:-2.77
High:0.7845
Open:0.7728
Low:0.7392
Close:0.7750
Loading ...

VolitionRX Announces Pricing of up to $2.3 Million Registered Direct Offering

THOMSON REUTERS
·
26 Mar

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

PR Newswire
·
25 Mar

VolitionRX Reports Positive Results of Automated Nu.Q Cancer Immunoassay Test in Development

MT Newswires Live
·
21 Mar

VolitionRx reports results from Nu.Q Cancer test

TIPRANKS
·
21 Mar

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
21 Mar

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

PR Newswire
·
20 Mar

BRIEF-Volition Signs First Ever Nu.Q Vet Cancer Test Automation Agreement With Fujifilm Vet Systems

Reuters
·
13 Mar

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
13 Mar

VolitionRx Signs Canine Cancer Test Automation Deal With Fujifilm Vet Systems

MT Newswires Live
·
13 Mar

Volition Signs First Ever Nu.q® Vet Cancer Test Automation Agreement With Fujifilm Vet Systems

THOMSON REUTERS
·
13 Mar

Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems

PR Newswire
·
13 Mar

Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test

PR Newswire
·
11 Mar

VNRX: Additional clinical papers & company webinars provide insights to Volition’s progress. Nu.Q Discover biomarkers selected for clinical trial. Management continues to focus on signing licensing deals for Capture-PCR & Nu.Q NETs

Zacks Small Cap Research
·
05 Mar

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
05 Mar

Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time

PR Newswire
·
04 Mar

Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference

PR Newswire
·
28 Feb

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
06 Feb

Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis

PR Newswire
·
06 Feb

Press Release: Volition to Host Virtual Investor Event on Nu.Q(R) NETs, "Casting a New Light on Sepsis Management", on February 14, 2025

Dow Jones
·
05 Feb

VolitionRx’s Nu.Q NETs biomarker shows predictive power in sepsis study

TIPRANKS
·
30 Jan